The management of brain edema in brain tumors

Current Opinion in Oncology

Volumn 16, Issue 6, 2004, Pages 593-600

  Kaal, Evert C A ^a   Vecht, Charles J ^a  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Blood brain barrier; Brain tumor; Corticosteroids; Edema; Imaging; Toxicity

Indexed keywords

ARACHIDONIC ACID; CORTICOTROPIN RELEASING FACTOR; COTRIMOXAZOLE; DEXAMETHASONE; GLUCOSE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE C4; PREDNISONE; PROTON PUMP INHIBITOR; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN EDEMA; BRAIN TUMOR; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GLIOMA; GLUCOSE METABOLISM; HUMAN; INTRACRANIAL TUMOR; MACROPHAGE; MENINGIOMA; MENTAL DISEASE; METABOLIC DISORDER; MOON FACE; MYOPATHY; NEGATIVE FEEDBACK; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENCHYMA; PATHOPHYSIOLOGY; PEPTIC ULCER; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN NEOPLASMS; DEXAMETHASONE; HUMANS; RANDOMIZED CONTROLLED TRIALS; WATER-ELECTROLYTE BALANCE;

EID: 8344241192     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000142076.52721.b3     Document Type: Review

References (81)

1. Pfund Z, Szapary L, Jaszberenyi O, et al.: Headache in intracranial tumors. Cephalalgia 1999, 19:787-790.
2. Forsyth PA, Posner JB: Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993, 43:1678-1683.
3. Christiaans MH, Kelder JC, Arnoldus EP, et al.: Prediction of intracranial metastases in cancer patients with headache. Cancer 2002, 94:2063-2068.
4. Posner JB: Overview. In Neurologic Complications of cancer. Edited by Posner JB. Philadelphia: FA Davis; 1995:1-14.
5. Posner JB: Intracranial metastases. In Neurologic Complications of Cancer. Edited by Posner JB. Philadelphia: FA Davis; 1995:77-110.
6. Thapar K, Taylor MD, Laws ER, et al: Brain edema, increased intracranial pressure, and vascular effects of human brain tumors. In Brain Tumors. An Encyclopedic Approach. Edited by Kaye AH, Laws ER. London: Churchill Livingstone; 2001:189-216. A comprehensive review describing brain tumor edema in detail. Recently discovered molecular mechanisms are obviously not included.
7. Milhorat TH: Classification of the cerebral edemas with reference to hydrocephalus and pseudotumor cerebri. Childs Nerv Syst 1992, 8:301-306.
8. Hiyama H, Kubo O, Tajika Y, et al.: Meningiomas associated with peritumoural venous stasis: three types on cerebral angiogram. Acta Neurochir (Wien) 1994, 129:31-38.
9. Philippen J, Foncin JF, Grob R, et al.: Cerebral edema associated with meningiomas: possible role of a secretory-excretory phenomenon. Neurosurgery 1984, 14:295-301.
10. Bitzer M, Nagele T, Geist-Barth B, et al.: Role of hydrodynamic processes in the pathogenesis of peritumoral brain edema in meningiomas. J Neurosurg 2000, 93:594-604. A study investigating the formation of edema in various types of meningiomas.
11. Reulen HJ, Huber P, Ito U, et al.: Peritumoral brain edema. A keynote address. Adv Neurol 1990, 52:307-315.
12. Furuse M, Hirase T, Itoh M, et al.: Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993, 123:1777-1788.
13. Furuse M, Fujita K, Hiiragi T, et al.: Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998, 141:1539-1550.
14. Hirase T, Staddon JM, Saitou M, et al.: Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997, 110:1603-1613.
15. Martin-Padura I, Lostaglio S, Schneemann M, et al.: Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998, 142:117-127.
16. Davies DC: Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002, 200:639-646. A useful review on molecular alterations in endothelial tight junctions in patients with brain tumors.
17. Papadopoulos MC, Saadoun S, Davies DC, et al.: Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 2001, 15:101-108. A review on the role of ocoludins, claudins and aquaporins in the endothelial tight junctions in brain tumors.
18. Papadopoulos MC, Saadoun S, Woodrow CJ, et al.: Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Meurobiol 2001, 27:384-395.
19. Liebner S, Fischmann A, Rascher G, et al.: Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol (Berl) 2000, 100:323-331.
20. Senger DR, Galli SJ, Dvorak AM, et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
21. Millauer B, Wizigmann-Voos S, Schnurch H, et al.: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
22. de Vries C, Escobedo JA, Ueno H, et al.: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255:989-931.
23. Connolly DT: Vascular permeability factor: a unique regulator of blood vessel function. J Cell Biochem 1991, 47:219-223.
24. Criscuolo GR: The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med 1993, 66:277-314.
25. Mayhan WG: VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am J Physiol 1999, 276:C1148-C1153.
26. Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997, 57:765-772.
27. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, et al.: Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997, 17:171-180.
28. Saadoun S, Papadopoulos MC, Davies DC, et al.: Aquaporin-4 expression is increased in oedematous human brain tumours. J Neurol Neurosurg Psychiatry 2002, 72:262-265.
29. Nishikawa R, Cheng SY, Nagashima R, et al.: Expression of vascular endothelial growth factor in human brain tumors. Acta Neuropathol (Berl) 1998, 96:453-462.
30. Pietsch T, Valter MM, Wolf HK, et al.: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol (Berl) 1997, 93:109-117.
31. Samoto K, Ikezaki K, Ono M, et al.: Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995, 55:1189-1193.
32. Maxwell M, Galanopoulos T, Hedley-Whyte ET, et al.: Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 1990, 46:16-21.
33. Speirs V, Boyle-Walsh E, Fraser WD: Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 1997, 72:714-719.
34. Machein MR, Plate KH: VEGF in brain tumors. J Neurooncol 2000, 50:109-120. A review describing the role of VEGF in gliomas, hemangioblastomas and meningiomas.
35. Plate KH, Breier G, Weich HA, et al.: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
36. Shweiki D, Itin A, Soffer D, et al.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
37. Leung SY, Chan AS, Wong MP, et al.: Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma. Am J Surg Pathol 1997, 21:941-950.
38. Mukhopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55:6161-6165.
39. Black KL, Hoff JT, McGillicuddy JE: Increased leukotriene C4 and vasogenic edema surrounding brain tumors in humans. Ann Neurol 1986, 19:592-595.
40. Nathoo N, Barnett GH, Golubic M: The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 2004, 57:6-13.
41. Gaetani P, Butti G, Chiabrando C, et al.: A study on the biological behavior of human brain tumors. Part I. Arachidonic acid metabolism and DNA content. J Neurooncol 1991, 10:233-240.
42. Hirashima Y, Hayashi N, Fukuda O, et al.: Platelet-activating factor and edema surrounding meningiomas. J Neurosurg 1998, 88:304-307.
43. Forman A: Altered mental status. In Cancer in the Nervous System. Edited by Levin VA. Oxford: University Press; 2002:543-547.
44. Shimizu T, Miki H, Takeguchi T, et al.: Usefulness of turbo-fluid-attenuated inversion-recovery (tFLAIR) sequence in diagnosing meningioma. Radiat Med 2003, 21:55-61.
45. Uematsu H, Maeda M, Itoh H: Peritumoral brain edema in intracranial meningiomas evaluated by dynamic perfusion-weighted MR imaging: a preliminary study. Eur Radiol 2003, 13:758-762.
46. Hino A, Imahori Y, Tenjin H, et al.: Metabolic and hemodynamic aspects of peritumoral low-density areas in human brain tumor. Neurosurgery 1990, 26:615-621.
47. Pennings FA, Bouma GJ, Kedaria M, et al.: Intraoperative monitoring of brain tissue oxygen and carbon dioxide pressures reveals low oxygenation in peritumoral brain edema. J Neurosurg Anesthesiol 2003, 15:1-5.
48. Meinig G, Reulen HJ, Simon RS, et al.: Clinical, chemical, and CT evaluation of short-term and long-term antiedema therapy with dexamethasone and diuretics. Adv Neurol 1980, 28:471-489.
49. Cloughesy TF, Black KL: Peritumoral edema. In The Gliomas. Edited by Berger MS, Wilson CB. Philadelphia: WB Saunders; 1999:107-114.
50. Bedford RF, Morris L, Jane JA: Intracranial hypertension during surgery for supratentorial tumor: correlation with preoperative computed tomography scans. Anesth Analg 1982, 61:430-433.
51. Ciric I, Ammirati M, Vick N, et al.: Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 1987, 21:21-26.
52. Fadul C, Wood J, Thaler HT, et al.: Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology 1998, 38:1374-1379.
53. Weiss HD: Neoplasms. In Manual of Neurologic Therapeutics. Edited by Samuels MA. Boston: Little, Brown and Company; 1995:224-229.
54. Grisold W, Krauseneck P, Muller B: Praktische Neuroonkologie. Vienna: Springer; 2000.
55. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 1998, 42:1083-1099.
56. Ruderman N, Hall T: Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 1965, 18:298-306.
57. Jelsma R, Bucy PC: The treatment of glioblastoma multiforme of the brain. J Neurosurg 1967, 27:388-400.
58. Yamada K, Ushio Y, Hayakawa T: Effects of steroids on the blood-brain barrier. In Implications of the Blood-Brain Barrier and Its Manipulation. Edited by Neuwelt EA. New York: Plenum Press; 1989:53-76.
59. Heiss JD, Papavassiliou E, Merrill MJ, et al.: Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996, 98:1400-1408.
60. Machein MR, Kullmer J, Ronicke V, et al.: Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999, 25:104-112.
61. Shapiro WR, Hiesiger EM, Cooney GA, et al.: Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma. J Neurooncol 1990, 8:197-204.
62. Leiguarda R, Sierra J, Pardal C, et al.: Effect of large doses of methylprednisolone on supratentorial intracranial tumors. A clinical and CAT scan evaluation. Eur Neurol 1985, 24:23-32.
63. Hatam A, Bergstrom M, Yu ZY, et al.: Effect of dexamethasone treatment on volume and contrast enhancement of intracranial neoplasms. J Comput Assist Tomogr 1983, 7:295-300.
64. Vecht CJ, Hovestadt A, Verbiest HB, et al.: Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994, 44:675-680. The only randomised study on dose-dependent toxicity of corticosteroids in patients with brain tumors.
65. Batchelor TT, Taylor LP, Thaler HT, et al.: Steroid myopathy in cancer patients. Neurology 1997, 48:1234-1238.
66. Meyer G, Badenhoop K: Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy. Med Klin 2003, 98:266-270.
67. Gotzsche PC: Steroids and peptic ulcer: an end to the controversy? J Intern Med 1994, 236:599-601.
68. Conn HO, Poynard T: Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994, 236:619-632.
69. Wen PY, Marks PW: Medical management of patients with brain tumors. Curr Opin Oncol 2002, 14:299-307. A practical review focusing on management of patients with brain tumors including steroids.
70. Brown ES, Chandler PA: Mood and cognitive changes during systemic corticosteroid therapy. Primary care companion. J Clin Psychiatry 2001, 3:17-21.
71. Kovacs JA, Gill VJ, Meshnick S, et al.: New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286:2450-2460.
72. Amatruda TT, Hurst MH, D'Esopo ND: Certain endocrine and metabolic facets of the steroid withdrawal syndrome. J Clin Endocrinol 1965, 25:1207-1217.
73. Posner JB: Supportive care of the neuro-oncology patient. In Management in Neuro-oncology. Edited by Hildebrand J. Berlin: Springer-Verlag; 1992:89-103.
74. Tjuvajev J, Kolesnikov Y, Joshi R, et al.: Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 1998, 12:1-10.
75. Villalona-Calero MA, Eckardt J, Burris H, et al.: A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema. Ann Oncol 1998, 9:71-77.
76. Takamoto T, Sasaki M, Kuno T, et al.: Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. Kobe J Med Sci 2001, 47:181-191.
77. Zangari M, Anaissie E, Stopeck A, et al.: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004, 10:88-95.
78. Fiedler W, Mesters R, Tinnefeld H, et al.: A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003, 102:2763-2767.
79. Portnow J, Suleman S, Grossman SA, et al.: A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intra-cerebral 9L gliosarcomas. Neurooncology 2002, 4:22-25.
80. Weissman DE, Stewart C: Experimental drug therapy of peritumoral brain edema. J Neurooncol 1988, 6:339-342.
81. Del Maestro RF, Megyesi JF, Farrell CL: Mechanisms of tumor-associated edema: a review. Can J Neurol Sci 1990, 17:177-183.